|
![]() |
貨號 | 品名 | 規(guī)格 | 包裝 | 單價 | 貨期 | 庫存 |
JD200512100511 | 雷莫蘆單抗 | 99.40% | 5mg | 19800元 | 咨詢客服 | 3天 |
JD200512100456 | 雷莫蘆單抗 | 99.40% | 1mg | 8000元 | 咨詢客服 | 3天 |
性狀: | Ramucirumab 是人 VEGFR-2 拮抗劑,可用于治療實體瘤。Ramucirumab 是一種人源化單克隆抗體,可與 VEGFR-2 結(jié)合,阻止 VEGFR 配體 VEGF-A,VEGF-C 和 VEGF-D 結(jié)合 |
質(zhì)量標準: | Description Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors[1]. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D[2]. IC50 & Target[1][2] VEGFR-2 |
貯存: | Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5. |